Gavin Wilson

Gavin Wilson

Auto-generated profile, based on publicly available information

Gavin Wilson

Latner Thoracic Research Laboratories, University Health Network , Toronto, Ontario

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
AWAaron Wong
Aaron Wong
ADAllen Duong
Allen Duong
GWGavin Wilson
Gavin Wilson
JYJonathan Yeung
Jonathan Yeung
SMSonya MacParland
Sonya MacParland
MLMingyao Liu
Mingyao Liu

19 May 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
SMSajad Moshkelgosha
Sajad Moshkelgosha
ADAllen Duong
Allen Duong
GWGavin Wilson
Gavin Wilson
TATallulah Andrews
Tallulah Andrews
GBGregory Berra
Gregory Berra
SJStephen Juvet
Stephen Juvet

21 March 2025 in Science Advances
Verified
Journal Article
Open access
SMSajad Moshkelgosha
Sajad Moshkelgosha
LLLiran Levy
Liran Levy
SSShahideh Safavi
Shahideh Safavi
SKSumiha Karunagaran
Sumiha Karunagaran
GWGavin Wilson
Gavin Wilson
SJStephen Juvet
Stephen Juvet
Survival after lung transplantation is limited by chronic lung allograft dysfunction (CLAD), an alloimmune fibrotic process leading to death or retransplantation after a median of 6 years. Immunosuppression fails to prevent CLAD, suggesting the existence of drug-resistant alloimmune pathways. We used time-of-flight mass cytometry to identify cells enriched in the bronchoalveolar lavage of patients with subsequent acute lung allograft dysfunction (ALAD), a risk factor for CLAD. We show that CD4 + CD57 + PD1 + T cells emerge in stable patients, conferring risks for ALAD, CLAD, and death. These cells are senescent, secrete inflammatory cytokines, and fall into two oligoclonal subsets with putative cytotoxic and follicular helper functions. Last, they are associated with fibrosis in mouse and human lung allografts, where they localize near airway epithelium and B cells. Together, our findings reveal an inflammatory T cell population that predicts future lung allograft dysfunction and may represent a rational therapeutic target.

20 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSajad Moshkelgosha
Sajad Moshkelgosha
LLLiran Levy
Liran Levy
SSShahideh Safavi
Shahideh Safavi
SKSumiha Karunagaran
Sumiha Karunagaran
GWGavin Wilson
Gavin Wilson
SJStephen Juvet
Stephen Juvet
Lung transplantation is a life-saving therapy for end-stage pulmonary disease, but its long-term outlook is poor due to a high incidence of chronic lung allograft dysfunction (CLAD). CLAD results from alloimmune-mediated progressive fibrosis and culminates in death or the need for re-transplantation after a median of 6 years. Existing immunosuppression fails to prevent CLAD, suggesting the existence of alloimmune pathways resistant to these drugs. Here, we used mass cytometry to identify cell populations enriched in the bronchoalveolar lavage (BAL) of patients with subsequent allograft dysfunction. We show that CD4 + CD57 + PD1 + T cells emerge in stable lung transplant recipients in the first year post-transplant, conferring heightened risks for CLAD and death or re-transplantation. CD4 + CD57 + PD1 + T cells display features of senescence and secrete inflammatory cytokines. Cellular indexing by transcriptomes and epitopes (CITE-Seq) on BAL CD4 + T cells revealed the existence of 2 oligoclonal CD57 + subsets with putative cytotoxic and follicular helper functions. Finally, we observed that CD4 + CD57 + PD1 + T cells are associated with lung allograft fibrosis in a mouse model and in human explanted CLAD lungs, where they localize near airway epithelium and B cells. Together, our findings reveal the existence of an inflammatory T cell population that predicts future lung allograft dysfunction and may represent a rational therapeutic target in lung transplant recipients.

3 August 2026 in Bioinformatics
Verified
Journal Article
Open access
GWGavin W Wilson
Gavin W Wilson
SKSangeetha N Kalimuthu
Sangeetha N Kalimuthu
JYJonathan C Yeung
Jonathan C Yeung
Motivation: Accurate sequencing depth planning for UMI-based transcriptomic experiments currently relies on heuristic metrics such as reads per cell and sequencing saturation. However, sequencing saturation cannot uniquely determine molecular recovery because the relationship between these quantities depends on amplification heterogeneity. Results: Here we present NB-Lib, a modeling framework based on a zero-truncated negative binomial representation of reads per molecule that jointly estimates amplification heterogeneity and library complexity from transcriptomic libraries. Across 150 single-cell and spatial transcriptomic datasets, NB-Lib accurately reconstructs sequencing saturation curves and predicts sequencing depth requirements from shallow pilot sequencing experiments. We show that amplification heterogeneity and library complexity define a compact parameterization linking sequencing depth, saturation, and molecular recovery across transcriptomic platforms and explain substantial variation in sequencing cost and recovery between samples and technologies. Finally, we demonstrate that molecular recovery directly determines the reproducibility of low-abundance gene detection. Together, these results establish a unified framework for interpreting sequencing saturation, molecular recovery, and sequencing efficiency across UMI-based transcriptomic technologies. Availability: The scdepth package is available at https://github.com/gwlab-ca/scdepth. Code needed to reproduce the analyses presented in this work is available at https://github.com/gwlab-ca/scdepth_manuscript. A selection of raw data and all the post-processed data is available at https://doi.org/10.5281/zenodo.15518941.

7 April 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
HYH. Yamamoto
H. Yamamoto
ASA.T. Sage
A.T. Sage
GWG.W. Wilson
G.W. Wilson
JAJ. Allen
J. Allen
ZAZ. Anwar
Z. Anwar
JYJ.C. Yeung
J.C. Yeung